Cytori Therapeutics Expands Asia Pacific Celution(TM) System Distribution Network
Wednesday September 12, 9:00 am ET
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ:CYTX - News; Frankfurt:XMPA - News) expanded its Asia Pacific distribution network for the Celution(TM) System in reconstructive surgery. Two additional distributors will cover Korea, through Olympus Digital Networks Korea (ODNK), and China, through Shanghai Cosmo Medical Products Co., Ltd. (SCMP). These groups will guide and support regulatory clearances, oversee product sales and provide physician education and training in their respective territories.
"Asia-Pacific represents an important and growing reconstructive surgery market for Cytori," said Christopher J. Calhoun, chief executive officer of Cytori Therapeutics. "Aligning ourselves with ODNK expands upon, and reflects the growth in, our partnership with Olympus Corporation. In addition, we look forward to benefiting from SCMP's existing leadership in the reconstructive surgery market in China."
"We are pleased to be partnered with Cytori for the commercialization of their Celution(TM) System," said Il-Seok Bang, president of ODNK. "Regenerative medicine is an emerging field with a tremendous market opportunity in reconstructive surgery, where we believe there will be significant patient demand."
Cytori's Celution(TM) System is an innovative medical device that removes a patient's own regenerative cells from their adipose (fat) tissue in about an hour. The cells can then be delivered to the same patient at the bedside in the same surgical procedure.
Ministerium für außerplanetarische Angelegenheiten/